Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
34.72
+0.05 (0.14%)
At close: Sep 11, 2026, 4:00 PM EDT
33.57
-1.15 (-3.31%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Avalyn Pharma Market Cap
Avalyn Pharma has a market cap or net worth of $1.49 billion as of September 11, 2026.
Market Cap
1.49B
Enterprise Value
1.09B
1-Year Change
n/a
Ranking
Category
Stock Price
$34.72
ChartMarket Cap Chart
Since the IPO on April 30, 2026, Avalyn Pharma's market cap has increased from $752.62M to $1.49B, an increase of 97.74%. That is a compound annual growth rate of 540.55%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 1.49B | -3.17% |
| Sep 10, 2026 | 1.54B | -3.37% |
| Sep 9, 2026 | 1.59B | -4.63% |
| Sep 8, 2026 | 1.67B | 0.62% |
| Sep 4, 2026 | 1.66B | 5.50% |
| Sep 3, 2026 | 1.57B | -0.39% |
| Sep 2, 2026 | 1.58B | 0.85% |
| Sep 1, 2026 | 1.56B | 1.58% |
| Aug 31, 2026 | 1.54B | 0.12% |
| Aug 28, 2026 | 1.54B | -4.98% |
| Aug 27, 2026 | 1.62B | -1.43% |
| Aug 26, 2026 | 1.64B | -3.04% |
| Aug 25, 2026 | 1.69B | 1.35% |
| Aug 24, 2026 | 1.67B | -1.77% |
| Aug 21, 2026 | 1.70B | 3.34% |
| Aug 20, 2026 | 1.65B | -4.72% |
| Aug 19, 2026 | 1.73B | 0.28% |
| Aug 18, 2026 | 1.72B | 1.59% |
| Aug 17, 2026 | 1.70B | -2.55% |
| Aug 14, 2026 | 1.74B | 7.30% |
| Aug 13, 2026 | 1.62B | -2.14% |
| Aug 12, 2026 | 1.66B | 5.41% |
| Aug 11, 2026 | 1.57B | 2.60% |
| Aug 10, 2026 | 1.53B | 1.89% |
| Aug 7, 2026 | 1.50B | 3.73% |
| Aug 6, 2026 | 1.45B | 2.19% |
| Aug 5, 2026 | 1.42B | 4.13% |
| Aug 4, 2026 | 1.36B | 7.82% |
| Aug 3, 2026 | 1.26B | -1.01% |
| Jul 31, 2026 | 1.28B | -1.77% |
| Jul 30, 2026 | 1.30B | 4.31% |
| Jul 29, 2026 | 1.25B | 1.12% |
| Jul 28, 2026 | 1.23B | 0.62% |
| Jul 27, 2026 | 1.22B | -1.18% |
| Jul 24, 2026 | 1.24B | -5.99% |
| Jul 23, 2026 | 1.32B | 3.52% |
| Jul 22, 2026 | 1.27B | -1.07% |
| Jul 21, 2026 | 1.29B | 1.40% |
| Jul 20, 2026 | 1.27B | 1.17% |
| Jul 17, 2026 | 1.25B | 10.20% |
| Jul 16, 2026 | 1.14B | -6.28% |
| Jul 15, 2026 | 1.21B | -3.11% |
| Jul 14, 2026 | 1.25B | 1.58% |
| Jul 13, 2026 | 1.23B | -0.78% |
| Jul 10, 2026 | 1.24B | -2.97% |
| Jul 9, 2026 | 1.28B | -0.07% |
| Jul 8, 2026 | 1.28B | 1.83% |
| Jul 7, 2026 | 1.26B | 2.78% |
| Jul 6, 2026 | 1.23B | -7.00% |
| Jul 2, 2026 | 1.32B | -1.46% |
| Jul 1, 2026 | 1.34B | -8.35% |
| Jun 30, 2026 | 1.46B | 6.19% |
| Jun 29, 2026 | 1.37B | 0.94% |
| Jun 26, 2026 | 1.36B | 5.97% |
| Jun 25, 2026 | 1.28B | -3.69% |
| Jun 24, 2026 | 1.33B | -6.81% |
| Jun 23, 2026 | 1.43B | -2.06% |
| Jun 22, 2026 | 1.46B | 4.83% |
| Jun 18, 2026 | 1.39B | 7.30% |
| Jun 17, 2026 | 1.30B | 4.42% |
| Jun 16, 2026 | 1.24B | -2.37% |
| Jun 15, 2026 | 1.27B | -4.42% |
| Jun 12, 2026 | 1.33B | 7.16% |
| Jun 11, 2026 | 1.24B | -1.61% |
| Jun 10, 2026 | 1.26B | -0.49% |
| Jun 9, 2026 | 1.27B | 2.17% |
| Jun 8, 2026 | 1.24B | 3.70% |
| Jun 5, 2026 | 1.20B | 0.26% |
| Jun 4, 2026 | 1.20B | 2.23% |
| Jun 3, 2026 | 1.17B | 2.69% |
| Jun 2, 2026 | 1.14B | -3.53% |
| Jun 1, 2026 | 1.18B | -7.37% |
| May 29, 2026 | 1.28B | 1.37% |
| May 28, 2026 | 1.26B | 5.85% |
| May 27, 2026 | 1.19B | 0.45% |
| May 26, 2026 | 1.18B | -7.42% |
| May 22, 2026 | 1.28B | 1.51% |
| May 21, 2026 | 1.26B | 1.36% |
| May 20, 2026 | 1.24B | -0.28% |
| May 19, 2026 | 1.25B | 5.56% |
| May 18, 2026 | 1.18B | -10.76% |
| May 15, 2026 | 1.32B | -2.55% |
| May 14, 2026 | 1.36B | -0.68% |
| May 13, 2026 | 1.37B | 3.11% |
| May 12, 2026 | 1.32B | 1.12% |
| May 11, 2026 | 1.31B | 8.20% |
| May 8, 2026 | 1.21B | 1.49% |
| May 7, 2026 | 1.19B | -2.81% |
| May 6, 2026 | 1.23B | 1.02% |
| May 5, 2026 | 1.22B | -5.64% |
| May 4, 2026 | 1.29B | -2.58% |
| May 1, 2026 | 1.32B | 75.69% |
| Apr 30, 2026 | 752.62M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Inhibrx Biosciences | 1.61B |
| AnaptysBio | 1.60B |
| Novavax | 1.55B |
| Bicara Therapeutics | 1.51B |
| Innoviva | 1.49B |
| Ascentage Pharma Group International | 1.47B |
| Latigo Biotherapeutics | 1.47B |
| LB Pharmaceuticals | 1.44B |